Application of Plan-Do-Check-Act cycle in improving the quality of antitumor drugs intravenous admixture services

Objective To explore the effect of Plan-Do-Check-Act (PDCA) circulation in improving the quality of anti-tumor drug configuration in pharmacy intravenous admixture services (PIVAS), and provide reference for improving the quality of anti-tumor drug configuration. Methods The pharmacists and nursing staff of the First Affiliated Hospital of Bengbu Medical College from February, 2016 to March, 2018 were enrolled into this study and assigned into the control group (February 2016-February 2017) and the study group (March 2017-March 2018) according to the time point. The control group was managed with the conventional drug allocation, while the study group with the PDCA cycle. The incidence and types of unreasonable anti-tumor drug allocation were compared between the two groups. Results The incidence of unreasonable anti-tumor drug allocation in the study group was 0.51% and in the control group was 0.88%, the difference was statistical significant (P<0.05). There was no significant difference between the study group and the control group in the unreasonable allocation of the selection of solvent, the dosage of drugs, the incompatibility of drugs and the selection of containers (P>0.05). The proportion of the unreasonable allocation solvent dose and drug storage conditions in the study group were both significantly lower than those of the control group, and the difference were statistically significant (P<0.05). Conclusion The PDCA cycle is an ideal management for PIAS, which can reduce the incidence of unreasonable anti-tumor drug configuration in the PIAS, including dose and storage conditions. It can promote the improvement of the configuration quality of anti-tumor drugs, and is worthy of application in the PIAS.